International study on inter-reader variability for circulating tumor cells in breast cancer.

Auteurs : Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart-Gebhart M, Borgen E, Naume B, Jimenez J, Aura CM, Zorzino L, Cassatella MC, Sandri MT, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K
Année : 2014
Journal : Breast Cancer Res
Volume : 16(2)
Pages : R43

Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.

Auteurs : Mokrim M, Aftimos P, Errihani H, Piccart-Gebhart M
Année : 2014
Journal : BMJ Case Rep
Volume : 2014(null)

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.

Auteurs : Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart-Gebhart M, Vobecky N, Thuresson M, Flamen P
Année : 2014
Journal : Breast Cancer Res. Treat.
Volume : 145(2)
Pages : 411-8

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Auteurs : Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart-Gebhart M, de Azambuja E, Loi S
Année : 2014
Journal : Breast
Volume : 23(4)
Pages : 473-81

Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Auteurs : Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart-Gebhart M, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C
Année : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1544-50

Controversial Issues in Early Stage Breast Cancer: a Global Collaborative Survey, supported by the European Society for Medical Oncology (ESMO).

Auteurs : Zardavas D, Ades F, Spasojevic IB, Pugliano L, Capelan M, Paesmans M, de Azambuja E, Piccart-Gebhart M
Année : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1558-62

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Auteurs : Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart-Gebhart M
Année : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 824-31

The landscape of medical oncology in Europe by 2020.

Auteurs : de Azambuja E, Ameye L, Paesmans M, Zielinski CC, Piccart-Gebhart M, Preusser M
Année : 2014
Journal : Ann Oncol
Volume : 25(2)
Pages : 525-8

Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast cancer in BOLERO-2.

Auteurs : Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart-Gebhart M
Année : 2014
Journal : Breast Cancer Res. Treat.
Volume : 143(3)
Pages : 459-67

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Auteurs : Zardavas D, Cameron D, Krop I, Piccart-Gebhart M
Année : 2013
Journal : Am Soc Clin Oncol Educ Book
Volume : null(null)

Emerging targeted agents in metastatic breast cancer.

Auteurs : Zardavas D, Baselga J, Piccart-Gebhart M
Année : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(4)
Pages : 191-210

Personalized therapy for breast cancer: a dream or a reality?

Auteurs : Zardavas D, Pugliano L, Piccart-Gebhart M
Année : 2013
Journal : Future Oncol
Volume : 9(8)
Pages : 1105-19

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Auteurs : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Année : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pages : 2621-32

Personalised cancer management: closer, but not here yet.

Auteurs : Piccart-Gebhart M
Année : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1951-5

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Auteurs : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Année : 2013
Journal : Adv Ther
Volume : 30(10)
Pages : 870-84

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.

Auteurs : Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart-Gebhart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA
Année : 2013
Journal : Curr Med Res Opin
Volume : 29(11)
Pages : 1463-73

Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.

Auteurs : Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart-Gebhart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M
Année : 2013
Journal : Clin Breast Cancer
Volume : 13(6)
Pages : 421-432.e8

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.

Auteurs : Partridge AH, Gelber S, Piccart-Gebhart M, Focant F, Scullion M, Holmes E, Winer EP, Gelber Rd
Année : 2013
Journal : J. Clin. Oncol.
Volume : 31(21)
Pages : 2692-8

Why your preferred targeted drugs may become unaffordable.

Auteurs : Piccart-Gebhart M
Année : 2013
Journal : Cancer Res
Volume : 73(19)
Pages : 5849-51